Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Latest story Refreshed every 5 minutes; wire stories every 15 minutesAbout this data
An investigational combination therapy from Eli Lilly led to significant weight loss in a mid-stage study, but high discontinuation rates raise questions about tolerability.
Eli Lilly & Co. announced that a new drug combination helped people with diabetes lose as much as 23% of their weight, more than other medicines in similar studies, suggesting it has the potential to be the drugmaker’s strongest obesity shot to date.
Eli Lilly & Co. is expected to pursue larger acquisitions, similar to its $7.8 billion deal for Centessa Pharmaceuticals Plc. CEO Dave Ricks indicated that the company is casting a wide net for assets in the unexplored areas of science.
Eli Lilly has committed $100 million in upfront and near-term payments to InnoCare Pharma to form a five-target drug discovery pact. The deal features up to $3.25 billion in milestones.
Viking Therapeutics' stock soared following the release of updated data from its obesity drug trial, indicating that trial participants mostly maintained their weight loss after switching from a weekly injection to a daily pill. In contrast, shares of competitors Eli Lilly rose while Novo Nordisk experienced a decline.
Viking Therapeutics' stock skyrocketed by 60% following the release of updated data from its obesity drug trials. The trial participants mostly kept their weight down after switching from a weight-loss drug to Viking's treatment, indicating promising results for the company's future in the obesity market.
Viking Therapeutics' stock surged by 50% following the release of updated data from its obesity drug trials. The trial participants mostly kept their weight down after switching from a weekly injection to a daily oral medication.
Viking Therapeutics Inc. shares surged after its dual-action obesity shot helped patients lose weight and keep it off, even after they cut their dosing schedule in a small, exploratory study.
Novo Nordisk A/S disappointed investors hoping for more concrete turnaround plans from Chief Executive Officer Mike Doustdar after the Danish drugmaker lost its lead in the booming obesity market to Eli Lilly & Co.
Novo Nordisk A/S disappointed investors hoping for more concrete turnaround plans from Chief Executive Officer Mike Doustdar after the Danish drugmaker lost its lead in the booming obesity market to Eli Lilly & Co.
Eli Lilly & Co. has surged about 300% since its first GLP-1 was approved over four years ago, propelling it past $1 trillion in market value and making it the world’s most valuable pharmaceutical company.
Novo Nordisk A/S will shorten its name for day-to-day use to just Novo in a bid to become more recognizable in its obesity market war with Eli Lilly & Co.
Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal
Foghorn to Slash 40% of Jobs as Lilly Cancer Partnership Falls Apart
Experimental Lilly combination drug tops Zepbound in weight-loss trial
A next-generation weight-loss drug from Eli Lilly, when combined with Zepbound, helped people lose substantially more weight than Zepbound alone, according to a new study
Lilly's experimental drug cuts weight by 21% in diabetes trial
Donald Trump, Cathie Wood Bet on the Same 32 Stocks – Some Might Surprise You
FDA approves Eli Lilly's once-weekly insulin injection for type 2 diabetes
US FDA approves Lilly's once-weekly insulin injection for type 2 diabetes
China's InnoCare, Eli Lilly sign collaboration deal worth up to $3.35 billion